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The putative tumour suppressor 
protein Latexin is secreted by 
prostate luminal cells and is 
downregulated in malignancy
Robert I. Seed1, Alberto J. Taurozzi1, Daniel J. Wilcock1, Giovanna Nappo1, Holger H. H. Erb  1,  
Martin L. Read  3, Mark Gurney  5, Leanne K. Archer1, Saburo Ito6, Martin G. Rumsby1, 
John L. Petrie2, Aled Clayton4, Norman J. Maitland1 & Anne T. Collins1
Loss of latexin (LXN) expression negatively correlates with the prognosis of several human cancers. 
Despite association with numerous processes including haematopoietic stem cell (HSC) fate, 
inflammation and tumour suppression, a clearly defined biological role for LXN is still lacking. 
Therefore, we sought to understand LXN expression and function in the normal and malignant prostate 
to assess its potential as a therapeutic target. Our data demonstrate that LXN is highly expressed 
in normal prostate luminal cells but downregulated in high Gleason grade cancers. LXN protein is 
both cytosolic and secreted by prostate cells and expression is directly and potently upregulated 
by all-trans retinoic acid (atRA). Whilst overexpression of LXN in prostate epithelial basal cells did 
not affect cell fate, LXN overexpression in the luminal cancer line LNCaP reduced plating efficiency. 
Transcriptome analysis revealed that LXN overexpression had no direct effects on gene expression 
but had significant indirect effects on important genes involved in both retinoid metabolism and IFN-
associated inflammatory responses. These data highlight a potential role for LXN in retinoid signaling 
and inflammatory pathways. Investigating the effects of LXN on immune cell function in the tumour 
microenvironment (TME) may reveal how observed intratumoural loss of LXN affects the prognosis of 
many adenocarcinomas.
Prostate cancer (CaP) is now the most prevalent non-cutaneous cancer in men1. Despite the success of surgical 
intervention, radiotherapy and androgen ablation therapies, there remains a significant recurrence rate of up to 
30%2,3. Such recurrences almost inevitably lead to more aggressive and treatment-resistant cancer such as castrate 
resistant and neuroendocrine tumours4. Therefore, by improving our knowledge of the human prostate it could 
be possible to devise new rational therapeutics which target the unmet clinical need of treatment resistant disease.
Latexin (LXN) was first discovered in the lateral neocortex of rats and serves as a marker of neuronal develop-
ment5. More recently LXN has been identified as a quantitative trait gene responsible for the negative regulation 
of haematopoietic stem cells (HSC) in mice6,7. Other studies suggest that increased LXN expression is associated 
with inflammatory responses such as acute pancreatitis and inflammatory lung disease8. In mouse models, LXN 
is found to be both highly expressed in inflammatory Mast cells and is induced following stimulation of mouse 
macrophages9,10
Several additional studies have also linked loss of LXN expression with numerous human malignancies, such 
as leukeamia11, melanoma12, hepatocellular carcinoma13 and pancreatic ductal adenocarcinoma (PDAC)14. For 
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example, LXN expression was shown to significantly correlate with tumour size, histological grade, metastasis 
and clinical stage in PDAC, indicating that LXN may function as a tumour suppressor15. Despite its association 
with numerous malignancies, the normal function of LXN and subsequently its role in malignant progression 
remain enigmatic. Initially, LXN was reported to function as the sole endogenous Carboxypeptidase A4 (CPA4) 
inhibitor in mammals16, but more recent studies have shown that LXN can function independently of CPA411,17. 
Furthermore, in different cancer models the biological effects of LXN appear to be diverse and its biological func-
tion is increasingly multi-faceted.
The expression and function of LXN in the normal and malignant prostate also remain poorly characterised. 
A single publication to date demonstrates that LXN might be a retinoic acid responsive gene and impart tumour 
suppressive effects on CaP cells. In this study, transient knockdown of LXN in non-malignant cells resulted in 
increased cell motility, invasiveness and clonogenic capacity, and preliminary data in prostate epithelial cell lines 
suggested that transient overexpression of LXN may reverse these effects18. Such data highlight LXN as a poten-
tially interesting candidate for prospective therapeutic targeting of treatment resistant CaP.
Therefore, we aimed to further characterise the expression patterns and define a molecular function for LXN 
in the normal and malignant prostate in order to determine how potential loss of LXN signalling in advanced 
prostate cancer might be exploited as a rational therapeutic target in CaP.
LXN is highly expressed in prostate luminal cells but is downregulated in malignancy
To determine whether LXN is expressed in the human prostate we first screened several anti-LXN antibod-
ies and were able to validate a suitable candidate for detection of LXN protein expression via Western blotting 
(Supplementary Fig. S1A–E). Protein expression analysis of seven individual non-malignant prostate tissue 
homogenates revealed that LXN is expressed in the normal prostate (Fig. 1A). Prostate tissue is comprised of 
basal epithelial and terminally differentiated luminal cells surrounded by a fibromuscular stromal layer19,20. 
Figure 1. LXN is highly expressed in non-malignant prostate luminal cells and repressed in high Gleason 
grade tumours. (A) Western blot data to assess LXN protein expression in the non-malignant human prostate. 
Data from seven different tissue specimens GAPDH serves as a loading control*. (B) Direct cell sorting from 
uncultured human prostate tissue into basal, luminal and stromal fractions reveals that LXN is predominantly 
expressed in prostate luminal cells and 24.25 ± 5.41-fold greater than basal cells (p < 0.01). RT-PCR analysis 
from four separate tissue samples. (C) mRNA expression analysis of the luminal specific marker PSA confirms 
the technical success of the FACS approach. The PC3 and LNCaP cell lines were used as basal and luminal cell 
controls, respectively. (D) Comparison of LXN gene expression following sub-fractionation of primary cultures 
of basal epithelial cells into stem cells (SC), transit amplifying (TA) and committed basal (CB) cells. Data is 
representative of four different primary culture samples. (E) Western blot to compare LXN protein expression 
in normal and malignant prostate tissue. α-SMA and GAPDH were used as indicators of relative stromal 
abundance and total protein loading respectively*. (F) Scanning densitometry of (E). (G) Gene expression 
analysis Grasso et al. prostate database reveals that LXN mRNA expression is significantly reduced in metastatic 
prostate disease compared to normal prostate (p < 0.01). mRNA expression analysis is presented as 2 ∆ddct 
(LXN/RPLP0). *Full length, uncropped blots from (A,F) can be viewed in Supplementary Fig. S6.
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In the absence of a suitable antibody for immunohistochemistry (IHC), we isolated cells directly from uncul-
tured human prostate tissue and purified them in to separate basal, luminal and stromal cell fractions using 
fluorescence-activated cell sorting (FACS) (Supplementary Fig. S1F). Analysis of LXN mRNA expression in 
these subsamples revealed that whilst LXN is expressed in all fractions, luminal cells express 24.25 ± 5.41-fold 
(p = 0.004) greater levels than basal cells. Stromal cells also express LXN, but at similar levels to basal cells 
(Fig. 1B). Prostate specific antigen (PSA) and androgen receptor (AR) are luminal cell markers and confirmed 
the stringency of our cell sorting strategy when compared to control cell lines: PC3 cells (basal-type) and LNCaP 
(luminal-type) cells (Fig. 1C and Supplementary Fig. S1G). Oldridge et al. reported LXN mRNA expression to 
be significantly lower in normal prostate tissue stem cells compared to more differentiated basal cells18. However, 
when we analysed the mRNA expression levels of LXN across the basal epithelial cell hierarchy (stem cell, tran-
sit amplifying and committed basal19), we found that prostate tissue stem cells do not express significantly dif-
ferent levels of LXN compared to more differentiated basal cells (Fig. 1D). LXN expression has been reported 
to be repressed in many solid tumours including thyroid, hepatic and pancreatic carcinomas13,15,21. To under-
stand whether the same expression patterns were observed in normal versus malignant prostate, we homoge-
nised several normal and several high Gleason (>G8) grade prostate tissue specimens and compared the protein 
expression of LXN via Western blotting (Fig. 1E). To control for the relative abundance of stroma within each 
sample, we probed for smooth muscle actin (SMA) in addition to GAPDH. Our data suggest that LXN expres-
sion is repressed in cancerous prostate compared to normal (50%, p = 0.001, Fig. 1E,F). In-keeping with these 
findings we found samples > GL7 from the Taylor et al.22 database also showed significant reduction in LXN 
mRNA expression compared to normal or lower Gleason grade tumours (Supplementary Fig. S1H)22. In order 
to understand the wider relevance of this finding, we interrogated a publicly available dataset (Grasso et al. 2012) 
and found LXN mRNA levels to be significantly downregulated in metastatic prostate cancer specimens when 
compared to normal prostate tissue (Fig. 1G)23,24.
LXN is secreted by prostate epithelial cells
LXN has been reported to be a predominantly cytosolic protein in the leukeamic cell line FDC-P1, in murine 
HSCs and also in primary human breast adenocarcinoma14,17,25. However, Oldridge et al. (2013) presented pre-
liminary data to suggest that LXN may be a nuclear protein in the prostate. To test the findings of Oldridge et al. 
we characterised the subcellular distribution of LXN in human prostate cells. Interestingly, after purification of 
both nuclear and cytosolic fractions from several prostate epithelial cell lines we found LXN to be exclusively 
cytosolic (Fig. 2A) even after overexposure of Western blots (Supplementary Fig. S2A). Any LXN positivity in 
the nuclear fraction was accompanied by α-tubulin positivity, suggesting a small amount of cytosolic contam-
ination (Supplementary Fig. S2A). These findings are consistent with many other LXN studies, but oppose the 
results of Oldridge et al. As the LXN antibody was unsuitable for use in immunocytochemistry, we transiently 
overexpressed LXN with a haemagglutinin tag (LXN-HA) to observe LXN subcellular distribution using a highly 
specific anti-HA antibody (Fig. 2B and Supplementary Fig. S2B). We utilised α-tubulin, a cytoskeletal protein and 
TATA binding protein (TBP), a general transcription factor to demonstrate unbiased antibody access to the cyto-
solic and nuclear subcellular compartments following fixation and permeabilisation of cells. Using this approach, 
LXN-HA appeared to be predominantly cytosolic, with a diffuse cytosolic expression pattern. There was a lack 
of convincing plasma membrane staining, and no puncta typical of endosome location or staining of reticular 
networks consistent with ER, Golgi or mitochondrial localisation. To take an unbiased approach in the character-
isation of LXN subcellular distribution, we also tested to see whether LXN is a secreted protein. We were able to 
immunoprecipitate LXN from prostate epithelial cell culture conditioned medium using the anti-LXN antibody 
in comparison to an isotype matched antibody control (Fig. 2J and Supplementary Fig. S2C). In silico analysis of 
the LXN amino acid sequence predicted that LXN does not contain a signal peptide (Fig. 2C,D)26. From these 
analyses we hypothesised that LXN might be secreted non-classically via extracellular vesicles (EV). To test this 
hypothesis, we purified EVs from cell-free PC3-conditioned medium and demonstrated the presence of predom-
inantly small nano-particles in these isolates using Nanoparticle tracking analysis (Fig. 2E–L and Supplementary 
Fig. 2D,E). We tested LXN expression within the EV isolates and the soluble secreted fraction (Fig. 2K,L) and 
found that whilst we could detect a small amount of LXN in the total purified EV fraction, LXN was mostly 
present within the soluble secreted fraction (Fig. 2K). To exclude the possibility of LXN passively diffusing from 
dead or dying cells, we used tubulin to confirm that no contaminating intracellular proteins were present in the 
EV isolate or secreted fraction (Fig. 2L).
LXN reduces the plating efficiency of prostate luminal cells
LXN expression reportedly affects the growth of several different tumours. For instance, overexpression of LXN 
decreases proliferation in Lymphoma11. Furthermore, LXN can play a tumour suppressive role in several different 
adenocarcinomas13,15,18,21. To determine the biological effects of LXN in prostate epithelial cells, we generated len-
tiviral vectors to induce robust and stable overexpression of LXN in normal (PNT1A), Benign (BPH-1) and can-
cer cell lines P4E6 (basal-like) and LNCaP (luminal –like) (Fig. 3A). Compared to cells transduced with lentiviral 
control particles (Mock), overexpression of LXN did not affect the viability of any of the cell lines tested, including 
the luminal-like cancer cell line, LNCaP (Fig. 3B). LXN also had no significant effects on the proliferation of cell 
lines (Supplementary Fig. 3A). You et al.17 reported that LXN sensitises leukeamic cells to the effects of DNA 
damage following ionising radiation17. To understand if the same effects were seen when LXN was overexpressed 
in human prostate cells, we measured viability and apoptosis following exposure to a low (10 Gy) or high (75 Gy) 
dose of γ-irradiation. (Fig. 3C–H). Confirmation of the induction of DNA damage response pathways were 
assessed by γ-H2AX foci (data not shown). We observed a dose-dependent decrease in cell viability following 
DNA damage in BPH-1, P4E6 and LNCaP cells (Fig. 3C,E,G), which correlated with a dose-dependent increase 
in apoptosis (Fig. 3D,F,H). However, overexpression of LXN had no significant effect on these processes. We did 
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however see a small decrease in the viability of LXN overexpressing BPH-1 cells, compared to mock transduced 
controls, but this did not correlate with a corresponding increase in apoptosis. Additionally, we saw a decrease 
in apoptosis in LXN overexpressing BPH-1 cells, treated with 75 Gy of radiation, yet viability was not signifi-
cantly altered. Oldridge et al. showed that transient knockdown of LXN in the PNT1A prostate epithelial cell line 
repressed motility by 62.5%, and that subsequent transient overexpression of HA-tagged LXN increased motility 
by 29%18. Motility changes in stably transfected BPH-1 and PNT1A cells overexpressing LXN indicated a trend 
towards increased motility. However, we were unable to obtain statistical significance in any of the cell lines tested 
(Fig. 3I,J and Supplementary Fig. 3B). When the effects of LXN overexpression on the colony forming efficiency 
of primary prostate epithelial cells (which are predominately basal) were tested, it was found that LXN overex-
pression had no significant effect on either colony number or size (Fig. 3K). Interestingly, whilst LXN had little 
effect on basal cells of non-malignant or malignant origin, the plating efficiency of the luminal-like cancer cell 
line, LNCaP, which expressed undetectable levels of endogenous LXN, was significantly reduced (35.5% ± 4.1%, 
p = 0.0013) in the LXN stable overexpression line compared to mock transduced cells (Fig. 3L).
Figure 2. LXN is cytosolic and also secreted. (A) Western blot analysis from subcellular fractionation studies 
in three prostate epithelial cell lines to determine LXN subcellular localisation. Representative blot from four 
independent experiments/cell line. α-tubulin and TBP indicate the purity of the cytosolic and nuclear fractions 
respectively. W.C (whole cell lysate), C (cytosolic), N (nuclear). See Supplementary Fig. S7 for uncropped 
original blots at 3 different exposures. (B) Confocal microscopy depicting Immunocytochemistry of PNT1A 
cells following transient overexpression of LXN-HA (upper panel). α-tubulin (middle panel) and TBP (lower 
panel) demonstrate the unbiased accessibility of both the nuclear and cytosolic compartments using this 
approach (Scale bar = 20 µM). (C,D) in silico analysis using SignalP 4.0 software to predict the occurrence of 
signal peptides in protein amino acid sequences reveals that LXN does not contain a predicted Signal peptide, 
whereas CPA4 does. (E) Nanoparticle tracking analysis (NanoSight NS300, Malvern) of positive control beads 
consistent with the size of exosomal particles (110 nM diameter) to determine that EVs purified were consistent 
with the size of exosomes in (F,G,H and I) which represent the purified EV fractions from PC3 and PNT1A 
cells respectively. (J) Enrichment of LXN from cell culture conditioned media following immunoprecipitiation 
using a LXN specific antibody compared to an isotype control and conditioned media control (input). This gel 
has been cropped to bring different parts of the same gel together for concisness and clarity. See Supplementary 
Fig. S2 for the full blot with all additonal controls. (K) Western blots demonstrating the relative abundance of 
LXN within purified EVs versus soluble secreted fractions (EV depleted media). TSG101 serves as a marker for 
successful isolation of endo/lysosomal material from the extracellular space. (L) Western blot of EV depleted 
media at two separate time points in PNT1A or PC3 cell lines. Tubulin was used to demonstrate the absence 
of any contaminating cellular material. Full length uncropped blots for (K,L) can be viewed in Supplementary 
Fig. S8A,B.
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LXN is directly upregulated by atRA in prostate cells
LXN expression has been reported to be responsive to retinoic acid (atRA) treatment, for example, by proteomic 
analysis of atRA treated MCF-7 (breast epithelial) cells27. Moreover, LXN mRNA was reported to be upregulated 
in response to retinoic acid in prostate epithelial cell lines18. Considering the findings from previous studies, we 
decided to characterise the LXN response to atRA more thoroughly within the human prostate. To investigate 
the dynamics of the LXN response to atRA in the non-malignant prostate we employed the PNT1A cell line. 
We observed robust and significant induction of LXN mRNA expression within eight hours of treatment with 
1 µM atRA (30.57 ± 3.01-fold, p = 0.0006). In comparison, a positive control gene (HOXA1), was only upregu-
lated (3.65 ± 0.34-fold, p = 0.0015) at this time-point (Fig. 4A). Furthermore, treatment of PNT1A cells with 1 µM 
atRA resulted in induction of LXN protein expression after 24 hours, which continued to accumulate to 96 hours 
after treatment (Fig. 4B). These data are in accordance with the long-half-life of LXN (>24 hours) as measured in 
anisomycin half-life assays (Fig. 4C). Additionally, treatment of PNT1A cells for 24 hours with either 500 nM or 
1 µM atRA resulted in strong induction of LXN protein expression in a dose dependent manner (Fig. 4D). We then 
attempted to compare the induction of LXN mRNA expression with that of HOXA1 which is directly upregulated 
by atRA28–30. We found that LXN and HOXA1 were both induced from two hours following atRA treatment. The 
levels of LXN mRNA expression accumulated over an eight-hour time-course (Fig. 4E), peaking at 24 hours whilst 
HOXA1 expression peaked between eight & 24-hours (Supplementary Fig. S4A). We next validated our findings in 
near-patient, non-malignant, primary epithelium. Here, both HOXA1 and LXN mRNA were significantly upreg-
ulated following atRA treatment (4.83 ± 1.26-fold, p = 0.0158 and 3.73 ± 0.57-fold, p = 0.0015 respectively, n = 9), 
and in six out of seven primary samples, LXN protein expression was increased after 72 hours treatment with 1 µM 
retinoic acid (average 2.54 ± 0.34-fold induction, p = 0.031) (Fig. 4F,G,H respectively).
LXN indirectly induces a pro-inflammatory transcriptome signature
To further explore the function and mechanism of action of LXN in the human prostate we chose a transcrip-
tomic approach. To examine potentially direct effects of LXN on total cellular gene expression, we overexpressed 
LXN, along with a GFP reporter gene, in non-malignant primary prostate epithelial cells by lentiviral transduc-
tion of the heterogeneous cell population. We utilised GFP positivity and subsequent Western blotting for LXN, 
to confirm the earliest time at which LXN is significantly overexpressed at the protein level. This was found to be 
36 hours post transduction (Fig. 5A,B and Supplementary Fig. 5A). Subsequent transcriptome analyses of these 
Figure 3. LXN reduces the plating efficiency of prostate luminal cells. (A) Representative image from a Western 
blot (n = 4) showing robust stable overexpression of LXN protein in prostate epithelial cell lines following 
lentiviral transduction. See Supplementary Fig. S9 for full length uncropped blot images (B). Cell viability 
assays demonstrating the effects of LXN overexpression in non-malignant (PNT1A and BPH-1) and malignant 
(P4E6 and LNCaP) prostate epithelial cell lines. (C–H) The effects of low (10 Gy) and high (75 Gy) doses of 
γ-irradiation on the viability (C,E,G) and apoptosis (D,F,H) of prostate epithelial cell lines. (I,J) Wound scrape 
assays to determine the effects of LXN overexpression on wound healing and motility in BPH-1 and PNT1A 
cell lines. (K) Effect of LXN overexpression on the colony forming effeciency of primary prostate epithelial data 
representative of 3 patient samples (L). Plating efficiency assays in prostate epithelial cell lines (n = 3). NS = non-
significant. p = 0.0013.
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samples revealed that short-term overexpression of LXN did not significantly alter total cellular gene expression. 
This is further evidence in support of the predominantly cytosolic and extracellular localisation of LXN and lack 
of any predicted nuclear localisation signal (Fig. 2). In accordance with our PCR and Western blot data, LXN was 
observed to be upregulated 118.31-fold, p = 0.0075 (n = 4) 36 hours after lentiviral transduction, compared to 
cells transduced with control particles in the transcriptome arrays (Fig. 5C and Supplementary Fig. 5C–E).
To explore the long-term, and therefore indirect effects of LXN on gene expression, we selected non-malignant 
primary prostate epithelial cells overexpressing LXN or mock control lentiviral particles using a puromycin 
resistance cassette (Fig. 5D). Cells were confirmed to be overexpressing LXN via RT-PCR (average increase of 
418 ± 87.92-fold, p = 0.0032, n = 4) and Western blotting (Fig. 5E,F respectively). To identify genes that are mod-
ulated by stable overexpression of LXN, we again performed transcriptome analysis. Of 13570 genes, we identified 
256 (0.19%) that passed the criteria for selection (<−2 or >2 fold, p < 0.05). Of those, 131 (51.17%) were found 
to be up-regulated and 125 (48.83%) to be down-regulated in response to stable LXN overexpression (Fig. 5G and 
Supplemental Fig. S5C–E). Functional annotation of the differentially expressed genes included those involved 
in catalytic processes, immune cell differentiation and inflammation, such as the IFN-γ response (Fig. 5H,I and 
Supplementary Table S2). To assess the validity of these findings we utilised the Cancer genome atlas (TCGA) 
database to assess concurrence of LXN alterations in human cancer gene databases with the most differentially 
expressed genes in our transcriptome arrays31,32. 23 of 86 genes showed a statistically significant relationship 
(Table 1). Additionally, we decided to empirically validate a number of genes by using additional non-malignant 
primary prostate epithelial samples. We focused on differentially expressed genes linked to retinoic acid signal-
ling and metabolism as our data indicate a role for LXN in the response to retinoic acid. We found that LXN 
over expression caused significant upregulation of CYP1A1 (5.8 ± 0.85 -fold and LAMP-3 3.27 ± 0.53-fold) and 
repression of ALDH3A1 by 44% ± 4.1% (Fig. 5J, K,L respectively). However, we were unable to reproduce a sig-
nificant effect of LXN overexpression on ALDH1A3 expression after repeated measurement (0.92 ± 0.14-fold, 
p = NS, n = 9 and Fig. 5M). Finally, long-term overexpression of LXN in the luminal CaP cell line LNCaP also 
resulted in significant upregulation of CYP1A1 when compared to untransduced cells or cells transduced with 
control particles (6.42 ± 0.03-fold, p < 0.0001, n = 3) (Fig. 5N).
Figure 4. LXN is directly upregulated by the differentiation agent atRA in human prostate epithelial cells. 
(A) Significant induction of LXN (30.57 ± 3.011-fold p = 0.0006) and HOXA1 (3.65 ± 0.3421-fold p = 0.0015) 
mRNA expression in PNT1A cells 8 hrs after treatment with 1 µM atRA. RT-PCR analysis from 3 independent 
experiments. (B) A time-course showing significant induction of LXN protein expression from 24 hrs after 
treatment with 1 µM atRA. See Supplementary Fig. S10A,B for uncropped blots. (C) Protein half-life assay 
to determine the stability of LXN over a 24 hr time-course following treatment of PNT1A cells with 10 µM 
of the protein synthesis inhibitor anisomycin. The relatively unstable protein p53 serves as a positive control. 
See Supplementary Fig. S10C,D for uncropped blot images. (D) Dose dependent induction of LXN protein 
expression following treatment with 500 nM or 1 µM atRA. See Supplementary Fig. S10D,E for uncropped blot 
images. (E) Induction of LXN and HOXA1 mRNA expression over an 8 hr time-course following treatment 
with 1 µM atRA in PNT1A cells (n = 3). (F) Significant induction of HOXA1 (4.83-fold ± 1.26-fold p = 0.0158) 
and LXN (3.73 ± 0.57-fold p = 0.0015) mRNA expression in primary human prostate epithelial cells 24 hrs 
after treatment with 500 nM atRA (n = 9). (G) Assessment of LXN protein expression 72 hrs after treatment 
with 500 nM atRA in 9 individual primary prostate epithelial cell samples. Data obtained from 3 separate blots 
(indicated by hatched lines) (See Supplementary Fig. S11 for full sized uncropped blots and multiple exposures). 
Scanning densitometry of (F) revealed LXN to be significantly induced 2.54 ± 0.34- fold p = 0.0313 (n = 9).
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Discussion
LXN has been associated with numerous very different malignancies. For example, LXN expression is down-
regulated in lymphoma, gastric carcinoma and thyroid carcinoma11,21,33 and loss of LXN expression corre-
lates with diverse biological effects in different cancer cell lines15,17. Such findings suggest that LXN may be a 
multi-functional protein or exhibit cell type specific effects. Despite multiple attempts to determine a role for loss 
of LXN expression in adenocarcinoma, thorough characterisation of LXN in normal epithelia or malignancy is 
Figure 5. LXN indirectly induces a pro-inflammatory trancriptome signature. Lentiviral particles containing 
Mock control or LXN both with a GFP reporter gene were used to track overexpression of proteins after viral 
transduction. (A) Representative image of GFP expression in live prostate cells 36 hrs after viral transduction 
using an epifluorescence microscope. (B) Western blot data depicting a time-course to determine the earliest 
time after lentiviral transduction at which LXN is overexpressed. α-tubulin serves as a loading control.  
(C) Representative scatter plot to show differentially expressed genes 36 hrs after transduction of LXN (cut off 
was ± 2-fold change p < 0.05). LXN was found to be overexpressed 118.31-fold, p = 0.0075, (n = 4) at this time-
point after viral transduction. (D) Bright-field images depicting primary prostate cells 48 & 72 hrs after selection 
in puromycin. Cells were transduced with control particles (Mock) or LXN lentiviral particles both containing a 
puromycin resistance cassette. Non-transduced primary prostate epithelia (UT) demonstrate the success of viral 
transduction. (E) Lentiviral transduced cells were confirmed on average to be overexpressing LXN using RT-
PCR (418 ± 87.92-fold, p = 0.0032, n = 4). (F) Western blot demonstrating that lentiviral transduced primary 
prostate epithelia overexpress LXN protein compared to cells transduced with control particles (α-tubulin 
serves as a loading control). (G) Representative scatter plot to show differentially expressed genes 1 week after 
transduction of LXN (cut off was ± 2-fold change, p < 0.05). (H) Representative heatmap to demonstrate the 
largest gene expression changes in individual samples. (I) Funtional annotation of differentially expressed 
genes in response to LXN overexpresion (see Supplementary Table 1 for detailed list). (J,K,L) Independent 
validation of the effects of LXN overexpression on CYP1A1, LAMP-3 and ALDH3A1 in non-malignant primary 
prostate epithelia (n = 9) (M). ALDH1A3 mRNA expression was not found to be significantly affected by 
LXN overexpression. (N) Stable overexpression of LXN in the luminal-like cancer cell line LNCaP resulted in 
significant induction of CYP1A1 mRNA expression compared to untransduced cells (UT) or cells transduced 
with control particles (6.42 ± 0.03 -fold, p < 0.000, n = 3). mRNA expression is presented as fold change relative 
to cells transduced with control particles (Mock).
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Differentially expressed genes log odds ratio p-value adjusted p- value Tendency
LAMP3 >3 <0.001 <0.001 CO-OCCURRENCE
PLSCR1 >3 <0.001 <0.001 CO-OCCURRENCE
PARP14 >3 <0.001 <0.001 CO-OCCURRENCE
ZPLD1 >3 <0.001 <0.001 CO-OCCURRENCE
LINC02085 >3 <0.001 <0.001 CO-OCCURRENCE
DDX60L >3 <0.001 <0.001 CO-OCCURRENCE
DDX60 >3 <0.001 <0.001 CO-OCCURRENCE
SNORD72 >3 <0.001 <0.001 CO-OCCURRENCE
43348 >3 <0.001 <0.001 CO-OCCURRENCE
PHGDH >3 <0.001 <0.001 CO-OCCURRENCE
FAM129A >3 <0.001 <0.001 CO-OCCURRENCE
BST2 >3 <0.001 <0.001 CO-OCCURRENCE
HIST2H4B >3 <0.001 <0.001 CO-OCCURRENCE
HIST2H4A >3 <0.001 <0.001 CO-OCCURRENCE
STAT1 >3 <0.001 <0.001 CO-OCCURRENCE
MAGE4D >3 <0.001 <0.001 CO-OCCURRENCE
SNORA11D >3 <0.001 <0.001 CO-OCCURRENCE
SNORA11E >3 <0.001 <0.001 CO-OCCURRENCE
SULT1E1 >3 <0.001 <0.001 CO-OCCURRENCE
MAGED4B >3 <0.001 <0.001 CO-OCCURRENCE
RSAD2 >3 <0.001 0.001 CO-OCCURRENCE
HERC5 >3 <0.001 0.003 CO-OCCURRENCE
TAPBPL >3 <0.001 0.003 CO-OCCURRENCE
GPNMB 2.785 <0.001 0.003 CO-OCCURRENCE
GP1BB >3 <0.001 0.007 CO-OCCURRENCE
KMO 2.563 <0.001 0.011 CO-OCCURRENCE
ASNS 3 <0.001 0.028 CO-OCCURRENCE
LBH >3 <0.001 0.157 CO-OCCURRENCE
MX1 >3 <0.001 0.211 CO-OCCURRENCE
IFIH1 2.43 <0.001 0.507 CO-OCCURRENCE
CYP1A1 2.695 <0.001 0.956 CO-OCCURRENCE
TNRSF10D 2.272 <0.001 0.999 CO-OCCURRENCE
MIR421 >3 <0.001 1 CO-OCCURRENCE
RRBP1 2.582 <0.001 1 CO-OCCURRENCE
SNORD114-6 2.981 <0.001 1 CO-OCCURRENCE
IFI44L 2.33 <0.001 1 CO-OCCURRENCE
OASL 2.847 0.001 1 CO-OCCURRENCE
GBP4 2.175 0.002 1 CO-OCCURRENCE
COL26A1 2.084 0.002 1 CO-OCCURRENCE
PIP5K1B 2.441 0.003 1 CO-OCCURRENCE
MX2 2.4 0.003 1 CO-OCCURRENCE
BIRC3 1.443 0.004 1 CO-OCCURRENCE
H1F10 >3 0.005 1 CO-OCCURRENCE
IFI44 2.251 0.007 1 CO-OCCURRENCE
IRF1 2.904 0.011 1 CO-OCCURRENCE
ATF3 2.063 0.018 1 CO-OCCURRENCE
MIR503 2.642 0.02 1 CO-OCCURRENCE
EPSTI1 2.373 0.024 1 CO-OCCURRENCE
SLC6A9 2.316 0.033 1 CO-OCCURRENCE
PARP6 2.21 0.038 1 CO-OCCURRENCE
OAS3 2.028 0.124 1 CO-OCCURRENCE
OAS2 1.948 0.171 1 CO-OCCURRENCE
MIR548F4 2.108 0.198 1 CO-OCCURRENCE
TAGLN 1.733 0.225 1 CO-OCCURRENCE
KIF20A 1.561 0.847 1 CO-OCCURRENCE
OAS1 1.414 0.885 1 MUTUAL EXCLUSIVITY
Continued
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still lacking. To further our understanding of LXN function in the normal and malignant prostate, we set out to 
understand where within the prostate cellular hierarchy LXN is expressed, investigate its subcellular localisation 
and characterise its biological role. We describe here for the first time, using an antibody extensively validated for 
use in Western blotting, that LXN is indeed robustly expressed in the human prostate. Furthermore, we found 
that, whilst LXN is expressed throughout the prostate, it is most highly expressed in luminal cells, suggesting a 
role in luminal cell function and/or differentiation. When we compared the expression levels of LXN between 
non-malignant and malignant prostate tissue, we found that LXN was significantly repressed in high Gleason 
grade cancers. Additionally, LXN expression was undetectable in two luminal type CaP lines (LNCaP and VCaP). 
These findings are interesting given that histologically, prostate cancers are predominantly luminal in pheno-
type, where LXN would appear to be most highly expressed, based on its normal epithelial cell expression19. 
Therefore, it is possible that transformed luminal cells may acquire a survival benefit by reducing levels of LXN. 
Finally, we found that metastatic prostate cancers also showed a striking down-regulation of LXN compared to 
non-malignant specimens. These data further raise the possibility that LXN expression is lost as CaP progresses. 
With further progression CaP cells become less differentiated and the luminal phenotype is lost, providing one 
explanation for loss of LXN expression.
Endogenously expressed LXN was observed to be cytosolic in prostate epithelia after subcellular fractionation, 
in keeping with the lack of any predicted NLS. These observations are in accordance with predictions from other 
studies15,17,33, but are in disagreement with the findings of Oldridge et al. whose preliminary findings suggest that 
ectopically expressed LXN-HA is a predominantly nuclear protein in prostate cells18. Our immunocytochem-
istry experiments also utilised ectopic overexpression of LXN-HA which is known to cause protein mislocali-
sation34–36. Despite this we still observed LXN to be predominantly cytosolic. Additionally, we now provide the 
first empirical evidence to suggest that LXN is secreted since we could find high levels in the conditioned media 
of several prostate epithelial cell lines. Given that our in silico analysis predicted that LXN lacks a signal peptide, 
we hypothesised that LXN might enter the extracellular space via EV release. Despite obtaining highly pure EV 
isolates from PNT1A or PC3 cell lines, we only found a small fraction of the total amount of secreted LXN to be 
present within vesicle isolates, and that there was negligible depletion of LXN from the secretome following ultra-
centrifugation at 100,000 x g. Therefore, it is more likely that LXN is secreted from cells via another mechanism, 
and future work would seek to determine the mechanism of LXN secretion. It is interesting to note that so-called 
leaderless proteins (lacking a signal peptide) can be secreted via numerous non-exosomal pathways37.
Differentially expressed genes log odds ratio p-value adjusted p- value Tendency
CHAC1 >3 0.895 1 MUTUAL EXCLUSIVITY
RCAN3 >3 0.936 1 MUTUAL EXCLUSIVITY
CCL5 >3 0.936 1 MUTUAL EXCLUSIVITY
SNORA44 >3 0.936 1 MUTUAL EXCLUSIVITY
SNORA61 >3 0.936 1 MUTUAL EXCLUSIVITY
SNORA16A >3 1 1 MUTUAL EXCLUSIVITY
SNHG12 >3 1 1 CO-OCCURRENCE
RNA5S2 >3 1 1 CO-OCCURRENCE
RNA5S3 >3 1 1 CO-OCCURRENCE
RNA5S1 >3 1 1 CO-OCCURRENCE
RNA5S4 >3 1 1 CO-OCCURRENCE
RNA5S5 >3 1 1 CO-OCCURRENCE
RNA5S11 >3 1 1 CO-OCCURRENCE
RNA5S12 >3 1 1 CO-OCCURRENCE
RNA5S13 >3 1 1 CO-OCCURRENCE
RNA5S14 >3 1 1 CO-OCCURRENCE
RNA5S15 >3 1 1 CO-OCCURRENCE
RNA5S16 >3 1 1 CO-OCCURRENCE
RNA5S6 >3 1 1 CO-OCCURRENCE
RNA5S7 >3 1 1 CO-OCCURRENCE
RNA5S8 >3 1 1 CO-OCCURRENCE
RNA5S10 >3 1 1 CO-OCCURRENCE
RNA5S17 >3 1 1 CO-OCCURRENCE
RNU6-1176P >3 1 1 CO-OCCURRENCE
RNU6-1291P >3 1 1 CO-OCCURRENCE
RNU61098P >3 1 1 CO-OCCURRENCE
MIR7976 >3 1 1 CO-OCCURRENCE
MT-TD >3 1 1 CO-OCCURRENCE
Table 1. TCGA data demonstrating the proportion of genes found to be indirectly regulated by LXN 
overexpression in prostate epithelial that also show concurrent genetic alterations with LXN in human 
cancer31,32.
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Next, we sought to determine the biological effects of LXN in prostate epithelial cells. Interestingly, robust 
and stable overexpression of untagged LXN did not significantly affect cell proliferation, viability or motility of 
prostate cell lines. LXN also did not appear to influence sensitivity to ionising radiation which is in contrast to the 
findings of You et al.17 who reported that LXN sensitises leukeamic cells to the effects of DNA damage following 
ionising radiation17. For these experiments we used two doses of ionizing radiation. The first, 10 Gy has been used 
to induce DNA damage in prostate epithelial cell lines38,39. However, whilst there was a clear trend, we were una-
ble to significantly reduce cell viability or increase apoptosis at this dose. In this setting LXN induced increases 
in sensitivity to ionizing radiation would likely be detectable compared to time-matched negative controls. The 
second dose 75 Gy is higher than usually performed in cell culture experiments and reflects the total dose of radi-
ation that patients undergoing radiation therapy receive over the course of several treatments40. Therefore, whilst 
our data suggest that LXN does not increase sensitivity to ionizing radiation at the doses used we acknowledge 
that our use of 75 Gy is quite high and that it is possible that LXN driven changes in the sensitivity to ionizing 
radiation may occur at lower doses. Intriguingly, LXN overexpression in primary prostate epithelial cells (which 
have a basal phenotype) did not significantly alter colony forming ability (an indicator of ‘stemness’) but did 
significantly reduce the plating efficiency of the luminal-type LNCaP cell line. Therefore, whilst LXN overexpres-
sion did not alter the viability of LNCaP cells, overexpression inhibited the ability of a subset of cells to adhere 
and therefore proliferate in culture. Such findings suggest that LXN may act as a tumour suppressor by reducing 
the ability of cancer cells to colonize metastatic sites. These data, together with our finding that LXN is mostly 
expressed in luminal cells and is secreted, suggest that LXN is likely to function predominantly within the prostate 
lumen or within luminal cells. Moreover, given that LXN appears to be downregulated in CaP, our data indicates 
that loss of LXN in luminal cells may be associated with malignant progression.
There is increasing evidence to suggest that LXN may be retinoid-responsive18,27. We have demonstrated for 
the first time that LXN is induced by retinoic acid (atRA) at both the mRNA and protein level, in both human 
prostate cell lines and primary prostate epithelia. LXN is directly and rapidly upregulated by atRA with similar 
kinetics to those of HOXA1, a well characterised primary gene expression response to atRA30. Interestingly, we 
found LXN protein to be extremely stable with a half-life exceeding 24 hours (a proteomic study in a bladder 
cancer cell line suggested 48 hour half-life28,41). These findings suggest that LXN may play a direct and lasting 
downstream role in the biological response to retinoids. One possible mechanism by which LXN may influence 
or regulate retinoic acid metabolism is through its proposed enzyme inhibitory function42. Given that LXN is 
induced directly by retinoic acid, it may form part of a feedback loop and function to inhibit enzymes involved in 
the metabolism of pre-cursor retinoids into atRA, thus helping to regulate atRA responses.
Transcriptome analyses of short-term overexpression of LXN did not yield any significant changes in gene 
expression. This finding, along with our demonstration that LXN is a secreted protein with limited access to the 
nuclear compartment, indicate that LXN does not function as a direct regulator of gene expression within the 
prostate epithelium. In contrast, long-term overexpression of LXN did result in transcriptomic changes, reveal-
ing that LXN regulates gene expression indirectly. Functional annotation of genes indirectly regulated by LXN 
overexpression include those involved in catalytic processes, and genes involved in immune cell function and 
inflammatory processes such as the response to IFN. These findings are supported by several studies linking LXN 
expression to inflammatory responses42–46. For example siRNA knockdown of MAFB in mouse macrophages 
resulted in significant anti-inflammatory responses which included significant reductions in levels of LXN, 
OAS1 OAS2, MX2 and IFNl4444. In another study, treatment of retinal pigment epithelium (RPE) cells with 
amyloid-β1-40, a known inflammatory trigger in Age-related macular degeneration (AMD) caused a significant 
induction of inflammatory genes such as BST2, STAT1, RSAD2, MX2, OAS1&2, IFNL44 and LXN43. Finally, 
LXN, OAS1&2 and MX2 were observed to be upregulated in liver cirrhosis compared to normal liver45. Our 
finding that LXN overexpression potentially increases immune signaling, possibly through IFN-γ and its related 
genes is further supported by several studies that highlight the synergy between interferons and atRA in clearing 
infection47,48, and increasing apoptosis in cancer cells49,50.
Our new data describes LXN as a predominantly luminal protein that is downregulated in high grade pri-
mary and metastatic disease. In contrast to previous work within the prostate, we describe LXN protein as both 
cytosolic and secreted rather than predominantly nuclear. LXN did not appear to be silenced in normal prostate 
tissue stem cells and overexpression did not appear to affect epithelial basal cell fate as previously described. 
We demonstrate that LXN is directly and lastingly upregulated by atRA and show that ectopic overexpression 
indirectly drives a pro-inflammatory immunomodulatory gene signature.Taken together these data suggest that 
LXN may play a functional role as a secreted ligand in the inflammatory response6,25. For instance, LXN may be 
secreted by epithelial cells and influence immune cell differentiation, recruitment and/or activity. This would 
be in broad agreement with the LXN knockout mouse phenotype, which results in an over-representation of 
haematopoietic stem-like cells in bone marrow6,7. Therefore, loss of LXN expression by tumour cells might be a 
novel mechanism of tumour immune cell evasion, for instance by blocking maturation of B and T cells. This could 
provide a survival benefit in vivo by preventing adequate anti-tumour immune responses. Our findings therefore 
highlight the importance of future study into the effects of LXN on immune cell infiltration and function within 
the tumour micro-environment.
Materials and Methods
We confirm that all research in this study was performed in accordance with local guidelines and (NHS Research 
Ethics Approval (REC) 07/H1304/121).
Culture of Prostate Cell lines. PNT1A, PC3 and LNCaP cells were purchased from American Type 
Culture Collection (ATCC). P4E6 were derived in our laboratory51 and BPH1 were a kind gift from Dr Hayward 
(NorthShore University HealthSystem Research Institute). PNT1A and LNCaP were cultured in Roswell Park 
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Memorial Institute medium (RPMI-1640) (Invitrogen Ltd) supplemented with 10% Foetal Calf Serum (FCS), 
and 2 mM L-Glutamine (Invitrogen Ltd). BPH1 cells were cultured in RPMI-1640 supplemented with 5% FCS, 
and 2 mM L-Glutamine. P4E6 cells were cultured in Keratinocyte Serum-Free Medium (KSFM) (Invitrogen 
Ltd) supplemented with 2% FCS, 2 mM L-Glutamine, 5 ng/ml Epidermal Growth Factor (EGF), 50 µg/ml bovine 
pituitary extract (Invitrogen Ltd). PC3 cells were cultured in Ham’s F-12 medium (Lonza) supplemented with 
7% FCS and 2 mM L-Glutamine. All cell lines were cultured at low passage and routinely tested for Mycoplasma 
contamination (EZ-PCR kit; Geneflow).
Primary cell culture. Primary cultures were derived from patient prostate tissues as described in52. Samples 
were obtained with informed written consent and ethical approval (NHS Research Ethics Approval (REC) 07/
H1304/121). Tissue samples were provided along with histopathological analysis. Primary prostate epithelial cells 
were cultured in KSFM supplemented with 1% L-glutamine, 1 ng/ml GM-CSF, 2 ng/ml stem cell factor, 50 µg/ml 
bovine pituitary extract, 100 ng/ml cholera toxin, and 5 ng/ml epidermal growth factor on dishes pre-coated with 
collagen type 1. Early passage cultures were co-cultured with mitotically inactivated mouse embryonic fibroblast 
(STO) feeder cells. Cellular fractionation to enrich for α2β1hi/CD133+ (stem-like cells), α2β1hi/CD133− (tran-
sit amplifying, TA) and α2β1low (committed basal, CB) cells were conducted as previously described19. First 
adherence to collagen was used separate α2β1-hi and α2β1low cells. This was followed by MACS (Miltenyi Biotec 
Ltd.) selection using anti anti-human CD133 microbeads and selecting CD133+ cell as per the manufacturer’s 
instructions.
Lentiviral transduction. Stable overexpression in prostate epithelial cells was achieved using lentiviral 
vectors. Human LXN cDNA was cloned into the lentiviral vectors, pDEST-236 (puromycin resistance vector) 
or pDEST-298 (eGFP co-expression vector). Lentiviral vectors using the Invitrogen Gateway Recombination 
Cloning Technology (Life Technologies Ltd). All lentiviral backbone vectors used in this study were a kind gift 
from Dr Stephan Geley. The pDONOR221-Escherichia coli-β-glucuronidase (Mock) was used for the control vec-
tor pGLTR-MOCK (Life Technologies Ltd). Cells were transduced with lentiviral particles and stable overexpres-
sion established using selection in puromycin or visualisation of eGFP positivity following standard protocols.
Fluorescence activated cell sorting. Primary prostate tissue was digested as previously described19. Cells 
were harvested by layering the digestion supernatant onto lymphocyte separation media (MP biomedicals) and 
subsequent centrifugation. Epithelial cells were negatively enriched from stromal cells using magnetic labelled 
non-tumour cell depletion cocktail (Miltenyi Biotech). Resulting enriched epithelial cells were counted and 
stained with EPCAM-FITC, CD49b-APC and CD24-PE (Miltenyi Biotech), as per the manufacturer’s instruc-
tions. Epithelial cells were sorted on a MOFLO XDP using the following strategy: cells were gated from debris 
using FSC and SSC and live cells were gated based on Cytox blue negativity. Luminal Cells were sorted from the 
EPCAM+ CD24+ live cell population and Basal cells were sorted from the EPCAM+ CD24− CD49b+ cell pop-
ulations. The non-epithelial, stromal cells were then enriched by purging the MACS column following magnetic 
labelling.
Irradiation of cells. Cells were irradiated using an RS2000 X-Ray Biological Irradiator, containing a Comet 
MXR-165x-Ray Source (Rad-Source Technologies Inc., Suwanee, GA, USA). A dose of 60 Gy (STO cells) or 75 Gy 
(prostate cell lines) was administered with a dose rate of 0.08 Gy/s.
Subcellular fractionation. Nucleocytoplasmic fractionation cell lines and primary cells was performed 
using NE-PER Nuclear and Cytoplasmic Extraction kit (Thermo Fisher Scientific) according to the manufactur-
er’s protocol.
SDS-PAGE and Western blotting. Cell lysates were prepared in RIPA buffer as previously described53. 
Whole prostate tissue homogenates were prepared using TPER buffer (ThermoFisher scientific) according to the 
manufacturer’s instructions. Western blotting was performed as described previously53,54. Primary Antibodies 
used are listed in Supplementary Table S1. Western blots were cropped for use in figures using Adobe photoshop. 
Unedited Images are displayed in Supplementary Fig. S6–11.
mRNA extraction. Total RNA was extracted using RNeasy Mini Kit (Qiagen) according to the manufac-
turer’s instructions. If STO cells were present in the culture, they were detached using 0.25% trypsin EDTA for 
2 minutes at 37 °C. Determination of RNA quality and concentration was performed using a NanoDrop ND-1000 
spectrophotometer (Thermo Fisher Scientific) or via a Bioanalyser (Agilent).
cDNA Synthesis and Expression Analysis. Total RNA was reverse transcribed using Superscript III 
enzyme (Invitrogen) and random hexamers. RT-PCR reactions were performed using TaqMan gene expression 
assays and iTaq Universal Supermixes (Thermofiisher), according to the manufacturer’s protocol. The delta-delta 
Ct method was used to analyse the results of RT-PCR55. For relative quantification the target gene was normalised 
to the expression of a control gene (including RPLPO and 18S ribosomal RNA (18S). Affymetrix microarray 
analysis was performed by Eurofins using Affymetrix GeneChip® Human Transcriptome Array 2.0 and analysed 
using Transcriptome analysis software (TAC v4.0) (Invitrogen) according to standard protocols. A standardized 
cut-off of +/−2-fold change and a raw P value of <0.05 measured by 1-way ANOVA was used to select differen-
tially expressed genes.
Immunofluorescence. PNT1A Cells were fixed with 4% (w/v) paraformaldehyde pH 7.4 for 20 min prior 
to Permeabilisation using 0.5% (v/v) Triton X-100 for 25 min. After permeabilisation, cells were Blocked using 
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with 10% (v/v) goat serum diluted 1% (w/v) BSA in PBS for 30 min. Antibody staining and slide preparation 
was then performed as previously described53. Analysis was performed using a Nikon Eclipse TE300 fluorescent 
microscope (Nikon) or LSM 720 meta confocal microscope (Zeiss). Primary antibody dilutions used for immu-
nofluorescence are listed in Supplementary Table S2.
Cell Viability Assay. The alamarBlue assay (Invitrogen) was used to assess cell viability according to manu-
facturer’s instructions, to control for the potential effects of LXN on plating efficiency, Viability reads were nor-
malized to cell number using an automated cell counter.
Clonogenic recovery Assay. Primary prostate epithelial cells were transduced as previously described. 
Cells were harvested by trypsinisation, counted, and plated at a density of 20 live cells/well in a 6-well culture plate 
in triplicate. Cells were co-cultured in the presence of irradiated STO cells. Culture medium was replaced every 
48 hours. 14 days after plating, the plates were stained with crystal violet (PBS, 1% crystal violet, 10% ethanol). 
The number colonies as well as the number of cells in each colony were recorded.
Plating efficiency. PNT1A, BPH-1, P4E6 and LNCaP cells were transduced as previously described. Cells 
were incubated on standard tissue culture plastic before non-adhered cells were removed through medium 
exchange. Plating efficiency was calculated using the alamarBlue assay to determine the number of adherent 
viable cells and results corroborated using an automated cell counter.
Scratch assay (wound closure). BPH-1 and PNT1A cells were transduced as previously described. Cells 
were plated at 80% confluency overnight. After 16 hours a wound was created using P1000 pipette tip. The width 
of wound was measured at relevant time points using Image J software. The average of 10 different measurements 
was taken and the relative percentage of wound closure was calculated relative to wound size at time point 0.
Extracellular vesicle purification. Extracellular vesicles were isolated from cell-conditioned media by 
serial centrifugation. Cell-conditioned media was centrifuged at 400 g, 5 min, 2,000 g, 15 min, 10,000 g, 40 min 
and subsequently by centrifugation at 100,000 g (Optima-MAX ultracentrifuge, with TLA110 rotor and Optiseal 
tubes, Beckman coulter) for 60 min to pellet vesicles. Alternatively, pre-cleared conditioned medium was overlaid 
onto a 30% sucrose, D2O cushion, and subject to centrifugation in a swing out rotor (MLS50, Beckman Coulter) 
for 90 mins. The collected sucrose was diluted in excess PBS, and vesicles were pelleted as above. This produced 
two experimental resources, a final pellet (of extracellular vesicles) and a supernatant (vesicle depleted media)56. 
Nano particle tracking analysis was employed to estimate the size of the vehicles purified using this methodology 
as we described56.
Protein Half-life Assay. BPH-1 cells were cultured in the presence of 10 µM anisomycin (Sigma-Aldrich) 
for 0, 2, 4, 8, 16 or 24 hours. Protein lysates were prepared in RIPA buffer. The amount of LXN and p53 protein was 
assessed using western Blot as previously described.
atRA treatment. Cells were cultured in the presence of atRA (Sigma-Aldrich) (typically 500 nM or 1 µM). 
Cells were harvested after treatment, time points ranged from 30 minutes to 96 hours depending on the exper-
imental requirements. Induction of LXN was analysed using RT-PCR and western blot. HOXA1 was used as a 
positive control for atRA mediated upregulation.
ApoTox-Glo™ Triplex Assay. Cell viability, cytotoxicity and apoptosis were assessed using the 
ApoTox-Glo™ Triplex Assay (Promega) according to the manufacturer’s instruction. Measurements were 
taken using a microplate reader (Polarstar Optima). Viability was measured at 505 nm (excitation at 400 nm). 
Cytotoxicity was measured 520 nm (excitation at 485 nm). Apoptosis was measured using luminescence.
Statistical analysis. All statistics were performed using the Graphpad Prism 7.0 software. Data is presented 
as mean and standard error of the mean (SEM) unless otherwise stated. To test the significance between 2 data 
sets we used the Man-whitney test. When comparing more than 2 means, ANOVA was used, unless otherwise 
stated.
Data Availability
The datasets generated during or analysed during the current study are available from the corresponding author 
on reasonable request.
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